360 related articles for article (PubMed ID: 17382374)
1. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.
McCubrey JA; Steelman LS; Franklin RA; Abrams SL; Chappell WH; Wong EW; Lehmann BD; Terrian DM; Basecke J; Stivala F; Libra M; Evangelisti C; Martelli AM
Adv Enzyme Regul; 2007; 47():64-103. PubMed ID: 17382374
[No Abstract] [Full Text] [Related]
2. RETRACTED ARTICLE: Investigating EGFR-VEGF-mediated apoptotic effect of cucurbitacin D and I combination with sorafenib via Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways.
Üremis N; Türköz Y; Üremiş MM; Çiğremiş Y; Şalva E
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3247. PubMed ID: 37917368
[No Abstract] [Full Text] [Related]
3. Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.
Yap JL; Worlikar S; MacKerell AD; Shapiro P; Fletcher S
ChemMedChem; 2011 Jan; 6(1):38-48. PubMed ID: 21110380
[No Abstract] [Full Text] [Related]
4. Untangling the signalling wires.
Kholodenko BN
Nat Cell Biol; 2007 Mar; 9(3):247-9. PubMed ID: 17330115
[TBL] [Abstract][Full Text] [Related]
5. Selective Raf inhibition in cancer therapy.
Khazak V; Astsaturov I; Serebriiskii IG; Golemis EA
Expert Opin Ther Targets; 2007 Dec; 11(12):1587-609. PubMed ID: 18020980
[TBL] [Abstract][Full Text] [Related]
6. Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters.
Umkehrer C; Holstein F; Formenti L; Jude J; Froussios K; Neumann T; Cronin SM; Haas L; Lipp JJ; Burkard TR; Fellner M; Wiesner T; Zuber J; Obenauf AC
Nat Biotechnol; 2021 Feb; 39(2):174-178. PubMed ID: 32719478
[TBL] [Abstract][Full Text] [Related]
7. Targeting a common collaborator in cancer development.
Myers AP; Cantley LC
Sci Transl Med; 2010 Sep; 2(48):48ps45. PubMed ID: 20826838
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
Ndubaku CO; Heffron TP; Staben ST; Baumgardner M; Blaquiere N; Bradley E; Bull R; Do S; Dotson J; Dudley D; Edgar KA; Friedman LS; Goldsmith R; Heald RA; Kolesnikov A; Lee L; Lewis C; Nannini M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Wallin JJ; Wang L; Wei B; Sampath D; Olivero AG
J Med Chem; 2013 Jun; 56(11):4597-610. PubMed ID: 23662903
[TBL] [Abstract][Full Text] [Related]
9. Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J; Dienstmann R; Serra V; Tabernero J
Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
[TBL] [Abstract][Full Text] [Related]
10. AKT/PKB signaling: navigating downstream.
Manning BD; Cantley LC
Cell; 2007 Jun; 129(7):1261-74. PubMed ID: 17604717
[TBL] [Abstract][Full Text] [Related]
11. The two TORCs and Akt.
Bhaskar PT; Hay N
Dev Cell; 2007 Apr; 12(4):487-502. PubMed ID: 17419990
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SGK1 potentiates the anticancer activity of PI3K inhibitor in NSCLC cells through modulation of mTORC1, p‑ERK and β‑catenin signaling.
Kale R; Samant C; Bokare A; Verma M; Nandakumar K; Bhonde M
Biomed Rep; 2023 Dec; 19(6):94. PubMed ID: 37901878
[TBL] [Abstract][Full Text] [Related]
13. Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents.
Rushing BR
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686047
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.
Li Q; Li Z; Luo T; Shi H
Mol Biomed; 2022 Dec; 3(1):47. PubMed ID: 36539659
[TBL] [Abstract][Full Text] [Related]
15. Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells.
Tian S; Su R; Wu K; Zhou X; Vadgama JV; Wu Y
J Pers Med; 2022 Aug; 12(8):. PubMed ID: 36013267
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Properties of N,N-dibenzylasparagine as an Asparagine (Asp) analog, Using Colon Cancer Caco-2 Cell Line.
Mohamed EA; Bassiouny K; Alshambky AA; Khalil H
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2531-2540. PubMed ID: 35901362
[TBL] [Abstract][Full Text] [Related]
17. The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword.
Heydarian M; Mohammadtaghizadeh M; Shojaei M; Babazadeh M; Abbasian S; Amrovani M
Mol Biol Rep; 2022 Jan; 49(1):605-615. PubMed ID: 34657251
[TBL] [Abstract][Full Text] [Related]
18. PIK3CB is involved in metastasis through the regulation of cell adhesion to collagen I in pancreatic cancer.
Qu J; Zheng B; Ohuchida K; Feng H; Chong SJF; Zhang X; Liang R; Liu Z; Shirahane K; Mizumoto K; Gong P; Nakamura M
J Adv Res; 2021 Nov; 33():127-140. PubMed ID: 34603784
[TBL] [Abstract][Full Text] [Related]
19. Erk phosphorylation reduces the thymoquinone toxicity in human hepatocarcinoma.
Zhang B; Ting WJ; Gao J; Kang ZF; Huang CY; Weng YJ
Environ Toxicol; 2021 Oct; 36(10):1990-1998. PubMed ID: 34173702
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
